2025 Finalists

Cernais develops an integrated approach based on artificial intelligence and conventional drug screening to identify new treatments for rare genetic diseases, particularly those related to the X chromosome, such as Rett syndrome and CDKL5 deficiency.

Dally Therapeutics is validating Dally, a modular app developed with patients and clinicians that covers the continuum of diabetes prevention and management, simplifying and improving the patients quality of life.

E.V.A. – Early Vesicles Analysis – is developing a graphene-based biosensor for early, rapid, specific, and scalable diagnosis for ovarian cancer screening.

Egiderma develops an advanced nano- and microstructured dressing system that allows for appropriate exudate management and the release of active components that accelerate the healing of complex wounds, particularly burns, preventing the formation of fibrous scars.

Fraido is developing a low-cost solution that reduces and speeds up difficult intubations and vascular accesses, capable of adjusting the diameter of the intubation device, particularly effective in emergency situations and complex intubations, reducing time and possible complications.

GeneSys Bio mission is to make rapid and accurate detection of key pathogens and antibiotic resistance available and accessible to everyone, anywhere and anytime.

HOPE is validating the repurposing of sitagliptin (an antidiabetic drug) for the treatment of dementia and neurodegeneration, particularly in Down syndrome, combined with a diagnostic system based on extracellular vesicles for monitoring brain health.

Lachesis Bio is developing an integrated platform combining artificial intelligence and animal models, based on transcriptomic data, to accelerate the identification of compounds that can influence longevity and age-related diseases.

MAAIReact is developing an app that assists individuals in preventing cognitive decline by providing a personalized plan with activities and suggestions based on scientific evidence to improve lifestyle, through a holistic approach across six dimensions (nutrition, physical activity, sleep, stress management, cognitive stimulation, and social engagement).

PROMOMIR is validating a multiplex diagnostic kit based on circulating microRNA for the non-invasive and early diagnosis of oral mucositis, to reduce its impact in chemotherapy or radiotherapy treatments for cancer patients, who develop these conditions in 40% of cases.

Rehabilia Technologies developed PhiCube, the PlayStation for habilitation, a portable modular robotic platform for multisensory stimulation, designed to transform play into effective and engaging learning experiences for children with developmental disorders..

TT3A is developing a medical device for the non-invasive treatment of patients with ascending aortic aneurysms to minimize the mortality rate associated with the treatment of this condition, today still approached with invasive procedures.